Cytosorbents Corp
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
CTSO$5.83+21.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · · Shares · · Par value · · Capital · · Income (Loss) · · Deficit · · Equity | |||||||||||||||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2023 | 54,240,265 | | $54 | | $306,187 | | $529 | | $(283,290) | | $23,480 | ||||||
| Stock-based compensation | — | | — | | 3,760 | | — | | — | | 3,760 | ||||||
| Issuance of common stock offerings, net of fees incurred | | 382,823 | | | 1 | | | 178 | | | — | | | — | | | 179 |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | | 207,058 | | | — | | | (7) | | | — | | | — | | | (7) |
| Issuance of warrants | | — | | | — | | | 691 | | | — | | | — | | | 691 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 3,723 | | | — | | | 3,723 |
| Net loss | — | | — | | — | | — | | (20,719) | | (20,719) | ||||||
| Balance at December 31, 2024 | 54,830,146 | | 55 | | 310,809 | | 4,252 | | (304,009) | | 11,107 | ||||||
| Stock-based compensation | | — | | | — | | | 2,765 | | | — | | | — | | | 2,765 |
| Common stock issued upon vesting of restricted stock units, less shares withheld to cover taxes | | 295,510 | | | — | | | — | | | — | | | — | | | — |
| Shares issued for exercise of stock options | | 11,650 | | | — | | | — | | | — | | | — | | | — |
| Issuance of common stock and warrants from rights offerings, net of fees incurred | | 6,249,791 | | | 6 | | | 5,386 | | | — | | | — | | | 5,392 |
| Issuance of common stock from exercise of warrants | 1,417,208 | | 2 | | 1,437 | | — | | — | | 1,439 | ||||||
| Issuance of warrants | — | | — | | 627 | | — | | — | | 627 | ||||||
| Foreign currency translation adjustment | | — | | | — | | | — | | | (7,229) | | | — | | | (7,229) |
| Net loss | — | | — | | — | | — | | (8,198) | | (8,198) | ||||||
| Balance at December 31, 2025 | 62,804,305 | | $63 | | $321,024 | | $(2,977) | | $(312,207) | | $5,903 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.